Necrotizing Fasciitis Empiric Therapy 

Updated: Mar 03, 2017
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Thomas E Herchline, MD  more...
  • Print
Sections

Empiric Therapy Regimens

General recommendations and empiric therapeutic regimens for necrotizing fasciitis are outlined below, including treatment based on Gram stain results and treatment for patients allergic to penicillin. [1, 2] Although necrotizing fasciitis is most often associated with bacterial infections, zygomycosis is an uncommon cause. Of 18 such patients with zygomycotic necrotizing fasciitis recently described, 15 were immunocompetent. [3] One must take fungal and bacterial cultures early, even in immunocompetent patients so antifungal therapy can be instituted. [4] However, instituting empiric therapy for fungi is not recommended. In the case of a cobra and other snake bite, identification of the snake and use of a specific antivenin may be pivotal. [5]

Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus (MRSA), an emerging phenomenon, must be considered, especially in endemic areas and high-risk situations such as jails and dormitories. Accordingly, specific empiric antibiotic therapy against MRSA is necessary. [6, 7]  

Hyperbaric oxygen therapy may also be used, especially if the infection is due to anaerobic organisms, although evidence to support or refute its value is lacking. [8] One can consider combining appropriate intravenous antibiotic therapy with conservative surgery and hyperbaric oxygen and negative-pressure wound therapy in an effort to preserve vital tissues and control the advancing infection. [9] Negative-pressure wound therapy with vacuum-assisted closure should be considered after wound debridement to enhance clinical benefit. [10]

Additional FDA-approved antibiotics for the treatment of acute bacterial skin and skin structure infections include oritavancin (Orbactiv), dalbavancin (Dalvance), and tedizolid (Sivextro). These agents are active against Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant S aureus [MSSA, MRSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus anginosus group (includes Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), among others. For complete drug information, including dosing, see the following monographs:

Surgical intervention is the major therapeutic modality in cases of necrotizing fasciitis:

  • Most patients with necrotizing fasciitis should return to the operating room 24-36h after the first debridement and then daily thereafter until the surgical team finds no further need for debridement
  • Antimicrobial therapy should continue for 48-72h after fever resolves, clinical improvement is evident, and no further surgical debridement is necessary
  • A Gram stain and, if suggested a fungal stain, of the exudate demonstrates the presence of pathogens and can provide an early clue to the preferred treatment recommendations [1]
  • If history reflects exposure to sewage-contaminated water, gram-negative coverage should be instituted for organisms such Pseudomonas and Aeromonas. [11]
  • MRSA is a significant in soft-tissue infections, becoming identified more frequently in necrotizing fasciitis. [12]

Treatment recommendations based on Gram stain result

Gram-positive cocci in chains:

Gram-positive rods:

  • Clindamycin 600 mg IV q8h or
  • Ampicillin-sulbactam 1.5-3 g IV q6h

Gram-negative rods or gram-positive cocci in clusters or mixed: [13]

  • Ampicillin-sulbactam 1.5-3 g IV q6-8h plus  clindamycin 600-900 mg IV q8h plus  ciprofloxacin 400 mg IV q12h or
  • Piperacillin-tazobactam 3.375 g IV q6-8h plus  clindamycin 600-900 mg IV q8h plus  ciprofloxacin 400 mg IV q12h or
  • Imipenem-cilastatin 1 g IV q6-8h or
  • Meropenem 1 g IV q8h or
  • Ertapenem 1 g IV q24h or
  • Cefotaxime 2 g IV q6h plus  ( metronidazole 500 mg IV q6h or clindamycin 600-900 mg IV q8h)
  • Since none of the above covers MRSA, in appropriate clinical situations consider vancomycin 1 g IV q12h, daptomycin 6-10 mg/kg IV q24h, [14] or linezolid 600 mg IV q12h

Treatment recommendations for penicillin-allergic patients

See the list below:

  • Clindamycin 600 mg IV q8h plus  ( vancomycin 15 mg/kg IV q12h or linezolid 600 mg PO or IV q12h) plus  ( aztreonam 1-2 g IV q6-8h or gentamicin 3-5 mg/kg/day IV in 3 divided doses or ciprofloxacin 400 mg IV q12h)

Guidelines

The Infectious Diseases Society of America recently updated their guidelines for the diagnosis and management of skin and soft tissue infections. For the full guidelines, see Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. [15, 16]